Carboplatin plus paclitaxel versus carboplatin plus pegylated liposomal doxorubicin as first-line treatment for patients with ovarian cancer: The MITO-2 randomized phase III trial

Journal of Clinical Oncology

Volumn 29, Issue 27, 2011, Pages 3628-3635

  Pignata, Sandro ^a   Scambia, Giovanni ^c   Ferrandina, Gabriella ^f   Savarese, Antonella ^d   Sorio, Roberto ^g   Breda, Enrico ^e   Gebbia, Vittorio ^h   Musso, Pietro ⁱ   Frigerio, Luigi ^k   Del Medico, Pietro ^l   Lombardi, Alessandra Vernaglia ^m   Febbraro, Antonio ⁿ   Scollo, Paolo ^o   Ferro, Antonella ^p   Tamberi, Stefano ^q   Brandes, Alba ^r   Ravaioli, Alberto ^s   Valerio, Maria Rosaria ^j   Aitini, Enrico ^t   Natale, Donato ^u   Scaltriti, Laura ^v   Greggi, Stefano ^a   Pisano, Carmela ^a   Lorusso, Domenica ^c   Salutari, Vanda ^c   Legge, Francesco ^f   Di Maio, Massimo ^a   Morabito, Alessandro ^a   Gallo, Ciro ^b   Perrone, Francesco ^a   more..

^a NATIONAL CANCER INSTITUTE   (Italy)

^b SECOND UNIVERSITY OF NAPLES   (Italy)

^c UNIVERSITÀ CATTOLICA DEL SACRO CUORE   (Italy)

^d REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^e SAN GIOVANNI CALIBITA FATEBENEFRATELLI HOSPITAL   (Italy)

^f CATHOLIC UNIVERSITY   (Italy)

^g CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

^h Casa di Cura La Maddalena ^*  (Italy)

ⁱ Azienda Ospedaliera di Rilievo Nazionale e di Alta Specializzazione Civico di Cristina Benfratelli   (Italy)

^j UNIVERSITY OF PALERMO   (Italy)

^k OSPEDALI RIUNITI   (Italy)

^l BIANCHI MELACRINO MORELLI HOSPITAL   (Italy)

^m Casa di Cura Malzoni Villa dei Platani   (Italy)

ⁿ Unit of Dermatology   (Italy)

^o CANNIZZARO HOSPITAL   (Italy)

^p SANTA CHIARA HOSPITAL   (Italy)

^q Ospedale Civile   (Italy)

^r BELLARIA HOSPITAL   (Italy)

^s OSPEDALE DEGLI INFERMI   (Italy)

^t CARLO POMA HOSPITAL   (Italy)

^u Ospedale S Massimo   (Italy)

^v Ospedale Ramazzini   (Italy)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; DOXORUBICIN; PACLITAXEL;

ANEMIA; ANOREXIA; AREA UNDER THE CURVE; ARTICLE; BLEEDING; BODY WEIGHT; CANCER COMBINATION CHEMOTHERAPY; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; CONSTIPATION; CONTROLLED STUDY; DIARRHEA; DISEASE SEVERITY; DRUG EFFICACY; DRUG FEVER; DRUG HYPERSENSITIVITY; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; HUMAN; KIDNEY DISEASE; LEUKOPENIA; LIVER INJURY; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROPATHY; NEUROTOXICITY; NEUTROPENIA; OPEN STUDY; OVARY CANCER; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; STOMATITIS; THROMBOCYTOPENIA; VOMITING;

ADULT; AGED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; DISEASE-FREE SURVIVAL; DOXORUBICIN; FEMALE; HUMANS; MIDDLE AGED; OVARIAN NEOPLASMS; POLYETHYLENE GLYCOLS; QUALITY OF LIFE;

EID: 80053074385     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2010.33.8566     Document Type: Article

References (27)

1. Jemal A, Siegel R, Ward E, et al: Cancer statistics, 2007. CA Cancer J Clin 57:43-66, 2007 (Pubitemid 46148091)
2. McGuire WP, Hoskins WJ, Brady MF, et al: Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 334:1-6, 1996 (Pubitemid 26012496)
3. Piccart MJ, Bertelsen K, James K, et al: Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: Three-year results. J Natl Cancer Inst 92:699-708, 2000 (Pubitemid 30365530)
4. Neijt JP, Engelholm SA, Tuxen MK, et al: Exploratory phase III study of paclitaxel and cisplatin versus paclitaxel and carboplatin in advanced ovarian cancer. J Clin Oncol 18:3084-3092, 2000
5. Du Bois A, Lućk HJ, Meier W, et al: A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/ paclitaxel as first-line treatment of ovarian cancer. J Natl Cancer Inst 95:1320-1329, 2003
6. Ozols RF, Bundy BN, Greer BE, et al: Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: A Gynecologic Oncology Group study. J Clin Oncol 21:3194-3200, 2003 (Pubitemid 46606249)
7. A'Hern RP, Gore ME: Impact of doxorubicin on survival in advanced ovarian cancer. J Clin Oncol 13:726-732, 1995
8. Muggia FM, Hainsworth JD, Jeffers S, et al: Phase II study of liposomal doxorubicin in refractoryovarian cancer: Antitumor activity and toxicity modification by liposomal encapsulation. J Clin Oncol 15:987-993, 1997 (Pubitemid 27106281)
9. Gordon AN, Tonda M, Sun S, et al: Long-term survival advantage for women treated with pegylated liposomal doxorubicin compared with topotecan in a phase 3 randomized study of recurrent and refractory epithelial ovarian cancer. Gynecol Oncol 95:1-8, 2004 (Pubitemid 39286270)
10. O'Byrne KJ, Bliss P, Graham JD, et al: A phase III study of Doxil/Caelyx versus paclitaxel in platinum-treated, taxane-naïve relapsed ovarian cancer. Proc Am Soc Clin Oncol 21:203a, 2002 (abstr 808)
11. Braud A, Goncalves A, Genre D, et al: Phase I study of liposomal doxorubicin (Caelyx) in combination with carboplatin (CBDCA) in patients with advanced or metastatic solid tumors. Proc Am Soc Clin Oncol 20:91b, 2001 (abstr 2113)
12. Verschraegen CF, Kavanagh JJ, Loyer E, et al: Phase II study of carboplatin and liposomal doxorubicin in patients with recurrent squamous cell carcinoma of the cervix. Cancer 92:2327-2333, 2001 (Pubitemid 33029076)
13. Ferrero JM, Weber B, Geay JF, et al: Secondline chemotherapy with pegylated liposomal doxorubicin and carboplatin is highly effective in patients with advanced ovarian cancer in late relapse: A GINECO phase II trial. Ann Oncol 18:263-268, 2007 (Pubitemid 46323091)
14. Therasse P, Arbuck SG, Eisenhauer EA, et al: New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 92:205-216, 2000 (Pubitemid 30099779)
15. Aaronson NK, Ahmedzai S, Bergman B, et al: The European Organization for Research and Treatment of Cancer QLQ-C30: A quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 85:365-376, 1993 (Pubitemid 23073154)
16. Schemper M, Smith TL: A note on quantifying follow-up in studies of failure time. Control Clin Trials 17:343-346, 1996 (Pubitemid 26342716)
17. Kaplan EL, Meier P: Nonparametric estimation from incomplete observation. J Am Stat Assoc 53:457-481, 1958
18. Mantel N: Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 50:163-170, 1966
19. Cox DR: Regression models and life tables. J R Stat Soc B 34:187-220, 1972
20. Pignata S, Scambia G, Savarese A, et al: Carboplatin and pegylated liposomal doxorubicin for advanced ovarian cancer: Preliminary activity results of the MITO-2 phase III trial. Oncology 76:49-54, 2009
21. Pignata S, Scambia G, Savarese A, et al: Safety of a 3-weekly schedule of carboplatin plus pegylated liposomal doxorubicin as first line chemotherapy in patients with ovarian cancer: Preliminary results of the MITO-2 randomized trial. BMC Cancer 6:202, 2006
22. Fayers PM, Aaronson NK, Bjordal K, et al: EORTC QLQ-C30 Scoring Manual (ed 3). Brussels, Belgium, European Organisation for Research and Treatment of Cancer, 2001
23. Pignata S, De Placido S, Biamonte R, et al: Residual neurotoxicity in ovarian cancer patients in clinical remission after first line chemotherapy with carboplatin and paclitaxel: The Multicenter Italian Trial in Ovarian cancer (MITO-4) retrospective study. BMC Cancer 6:5, 2006
24. Du Bois A, Weber G, Rochon J, et al: Addition of epirubicin as a third drug to carboplatin-paclitaxel in first-line treatment of advanced ovarian cancer: A prospectively randomized gynecologic cancer intergroup trial by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group and the Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens. J Clin Oncol 24:1127-1135, 2006 (Pubitemid 46638810)
25. Kristensen GB, Vergote I, Eisenhauer E, et al: First line treatment of ovarian/tubal/peritoneal cancer FIGO stage IIb-IV with paclitaxel/carboplatin with or without epirubicin (TEC vs TC): A Gynecologic Cancer Intergroup study of the NSGO, EORTC GCG, and NCIC CTG-Results on progression free survival. J Clin Oncol 23:448, 2004 (suppl; abstr 5003)
26. Pujade-Lauraine E, Wagner U, Aavall- Lundqvist E, et al: Pegylated liposomal doxorubicin and carboplatin compared with paclitaxel and carboplatin for patients with platinum-sensitive ovarian cancer in late relapse. J Clin Oncol 28:3323-3329, 2010
27. Bookman MA, Brady MF, McGuire WP, et al: Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: A phase III trial of the Gynecologic Cancer Intergroup. J Clin Oncol 27:1419-1425, 2009